课题基金 / 基金详情

New Function for the Serpin PAI-2 as a Regular of pRb

New Function for the Serpin PAI-2 as a Regular of pRb
Serpin PAI-2 作为 pRb 正则的新功能
批准号:
6782721
负责人:
Toni M Antalis
金额:
$31.99万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2008-07-31

项目摘要

项目成果

Toni M Antalis的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):信号转导分子的蛋白水解裂解是控制细胞生长、死亡和分化的重要机制,影响广泛的生理和病理过程。细胞内蛋白水解必须受到内源性抑制剂的严格调控。纤溶酶原激活物抑制剂2型(PAI-2)在结构和功能上是丝氨酸蛋白酶抑制剂或丝氨酸蛋白酶抑制剂大家族的成员。丝氨酸蛋白酶抑制剂是重要生物过程如补体激活、纤维蛋白溶解、凝血、细胞分化、肿瘤抑制、细胞凋亡和细胞运动的关键调节剂。PA 1 -2最初被表征为细胞外尿激酶型纤溶酶原激活物的抑制剂,然而PA 1 -2是一种低效分泌的丝氨酸蛋白酶抑制剂,其表现出核质分布。我们以前已经发现,PAI-2表达赋予抗凋亡和保护细胞免受某些细胞病变病毒在体外。我们的初步数据确定了PAI-2作为视网膜母细胞瘤肿瘤抑制因子(pRb)结合蛋白的细胞内活性,该蛋白可保护pRb免受蛋白水解降解。pRb蛋白家族是普遍存在的转录调节因子,在控制细胞增殖中起关键作用。本申请的中心假设是细胞内PAI-2稳定pRb和p130,并且在这样做时,促进与细胞周期停滞和促进分化、降低对E2 F1依赖性细胞凋亡的敏感性、转录调节和肿瘤抑制相关的pRb介导的活性。待测试的具体假设是:1)PA 1 -2结合pRb和相关口袋蛋白p130,2)PA 1 -2抑制pRb的蛋白水解切割,从而增强pRb水平和pRb介导的活性,和3)PA 1 -2通过pRb介导的稳定促进角质形成细胞和内皮细胞的存活。这些假设将通过1)利用其中特定功能已被破坏的突变蛋白表征PA 1 -2和pRb之间的特定分子相互作用,2)确定PA 1 -2稳定pRb的分子机制并评估钙蛋白酶样蛋白酶在介导pRb的蛋白水解切割中的作用,和3)使用PAI-2-/-小鼠模型测试PAI-2在稳定pRb中的体内功能。分析将具体评估PAI-2在角质形成细胞分化、内皮细胞增殖和血管生成中的作用。
英文摘要
DESCRIPTION (provided by applicant): Proteolytic cleavage of signal transduction molecules is an important mechanism for controlling cell growth, death and differentiation affecting a wide range of physiological and pathological processes. Intracellular proteolysis must be tightly regulated by endogenous inhibitors. Plasminogen activator inhibitor type 2 (PAl-2) is structurally and functionally a member of a large family of serine protease inhibitors or serpins. Serpins are key regulators of important biological processes such as complement activation, fibrinolysis, coagulation, cellular differentiation, tumor suppression, apoptosis and cell motility. PAl-2 was originally characterised as an inhibitor of the extracellular urokinase-type plasminogen activator, however PAl-2 is an inefficiently secreted serpin that exhibits a nucleocytoplasmic distribution. We have previously found that PAl-2 expression confers resistance to apoptosis and protects cells from certain cytopathic viruses in vitro. Our preliminary data identifies an intracellular activity for PAl-2 as a retinoblastoma tumor suppressor (pRb) binding protein that protects pRb from proteolytic degradation. The pRb family of proteins is ubiquitous regulators of transcription and plays a critical role in controlling cell proliferation. The central hypothesis of this application is that intracellular PAl-2 stabilizes pRb and p130, and in doing so, promotes pRb mediated activities associated with cell cycle arrest and promotion of differentiation, decreased sensitivity to E2F1 dependent apoptosis, transcriptional regulation and tumor suppression. The specific hypotheses to be tested are: 1) that PAl-2 binds pRb and the related pocket protein, p130, 2) that PAl-2 inhibits proteolytic cleavage of pRb, thereby enhancing pRb levels and pRb mediated activities, and 3) that PAl-2 promotes survival of keratinocytes and endothelial cells via pRb mediated stabilization. These hypotheses will be tested by 1) characterising the specific molecular interactions between PAl-2 and pRb utilizing mutant proteins in which specific functions have been disrupted, 2) determining the molecular mechanism by which PAl-2 stabilizes pRb and evaluating the role of calpain-like proteases in mediating proteolytic cleavage of pRb, and 3) testing the in vivo function of PAl-2 in stabilizing pRb using a PAl-2-/- mouse model. Analyses will specifically evaluate the roles of PAl-2 in keratinocyte differentiation, and endothelial cell proliferation and angiogenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer
  • 批准号:
    10204893
  • 项目类别:
  • 资助金额:
    $35.34万
  • 财政年份:
    2017
  • 负责人:
    Toni M Antalis
  • 依托单位:
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer
  • 批准号:
    9383843
  • 项目类别:
  • 资助金额:
    $35.34万
  • 财政年份:
    2017
  • 负责人:
    Toni M Antalis
  • 依托单位:
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer
  • 批准号:
    9975097
  • 项目类别:
  • 资助金额:
    $35.34万
  • 财政年份:
    2017
  • 负责人:
    Toni M Antalis
  • 依托单位:
UMB Postbaccalaureate Research Education Program
  • 批准号:
    10579976
  • 项目类别:
  • 资助金额:
    $35.78万
  • 财政年份:
    2016
  • 负责人:
    Toni M Antalis
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
  • 批准号:
    31970691
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    张胜萍
  • 依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
  • 批准号:
    31900527
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    孙磊
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位: